Additional assistance necessary for patients prescribed specialty therapies.
Julia Laurin
Advertisement
Articles by Julia Laurin
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
AI has Redefined Healthcare Communication — and There’s No Opting Out
2
How FDA's Removal of the Two-Trial Requirement Affects Development Programs
3
FDA Grants Priority Review to Enhertu as Treatment for Patients with HER2-positive Early Breast Cancer
4
Novo Nordisk Signs Deal with Hims & Hers
5